PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicity

Breast Cancer Research and Treatment

Volumn 115, Issue 1, 2009, Pages 29-41

  Gao, Jie ^a   Kou, Geng ^a,b   Wang, Hao ^a,b   Chen, Huaiwen ^a   Li, Bohua ^a,b   Lu, Ying ^a   Zhang, Dapeng ^a   Wang, Shuhui ^a   Hou, Sheng ^a,b   Qian, Weizhu ^a,b   Dai, Jianxin ^a   Zhao, Jian ^a   Zhong, Yanqiang ^a   Guo, Yajun ^a,b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Shanghai Center for Cell Engineering and Antibody   (China)

Author keywords

Breast cancer; Immunogenicity; Nanoparticles; PE38KDEL; RhuMAbHER2; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOTOXIN; NANOPARTICLE; PE38KDEL; PE38KDEL-HER2 IMMUNOGLOBULIN F(AB) FRAGMENT BIOCONJUGATE; PE38KDEL-POLY(LACTIC CO GLYCOLIC ACID)-HER2 IMMUNOGLOBULIN F(AB) FRAGMENT BIOCONJUGATE; POLYGLACTIN; RESOMER; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BREAST TUMOR; CANCER CELL; CANCER INHIBITION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; FEMALE; GENE OVEREXPRESSION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ALANINE TRANSAMINASE; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOTOXINS; MICE; MICE, INBRED BALB C; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASM TRANSPLANTATION; RECEPTOR, ERBB-2;

EID: 67349280404     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0043-0     Document Type: Article

References (45)

1. I Pastan R Hassan DJ Fitzgerald RJ Kreitman 2006 Immunotoxin therapy of cancer Nat Rev Cancer 6 559 565
2. I Pastan LH Pai U Brinkmann D FitzGerald 1996 Recombinant immunotoxins Breast Cancer Res Treat 38 3 9
3. I Pastan R Hassan DJ FitzGerald RJ Kreitman 2007 Immunotoxin treatment of cancer Annu Rev Med 58 221 237
4. H Ochiai GE Archer JE Herndon 2nd CT Kuan DA Mitchell DD Bigner IH Pastan JH Sampson 2008 EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells Cancer Immunol Immunother 57 115 121
5. RJ Kreitman 1999 Immunotoxins in cancer therapy Curr Opin Immunol 11 570 578
6. M Onda S Nagata Y Tsutsumi JJ Vincent Q Wang RJ Kreitman B Lee I Pastan 2001 Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity Cancer Res 61 5070 5077
7. LH Pai DJ FitzGerald M Tepper B Schacter G Spitalny I Pastan 1990 Inhibition of antibody response to Pseudomonas exotoxin and an immunotoxin containing Pseudomonas exotoxin by 15-deoxyspergualin in mice Cancer Res 50 7750 7753
8. R Hassan J Williams-Gould T Watson L Pai-Scherf I Pastan 2004 Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1 Clin Cancer Res 10 16 18
9. S Bang S Nagata M Onda RJ Kreitman I Pastan 2005 HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity Clin Cancer Res 11 1545 1550
10. RJ Kreitman DR Squires M Stetler-Stevenson P Noel DJ FitzGerald WH Wilson I Pastan 2005 Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies J Clin Oncol 23 6719 6729
11. Y Tsutsumi M Onda S Nagata B Lee RJ Kreitman I Pastan 2000 Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity Proc Natl Acad Sci USA 97 8548 8553
12. TM Allen PR Cullis 2004 Drug delivery systems: entering the mainstream Science 303 1818 1822
13. K Avgoustakis A Beletsi Z Panagi P Klepetsanis AG Karydas DS Ithakissios 2002 PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties J Control Release 79 123 135
14. R Lin L Shin Nq CH Wang 2005 In vitro study of anticancer drug doxorubicin in PLGA-based microparticles Biomaterials 26 4476 4485
15. I Brigger C Dubernet P Couvreur 2002 Nanoparticles in cancer therapy and diagnosis Adv Drug Deliv Rev 54 631 651
16. DC Litzinger AM Buiting N van Rooijen L Huang 1994 Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes Biochim Biophys Acta 1190 99 107
17. RK Visaria RJ Griffin BW Williams ES Ebbini GF Paciotti CW Song JC Bischof 2006 Enhancement of tumor thermal therapy using gold nanoparticle-assisted tumor necrosis factor-alpha delivery Mol Cancer Ther 5 1014 1020
18. IT Degim N Celebi 2007 Controlled delivery of peptides and proteins Curr Pharm Des 13 99 117
19. SJ Beer CB Matthews CS Stein BD Ross JM Hilfinger BL Davidson 1998 Poly (lactic-glycolic) acid copolymer encapsulation of recombinant adenovirus reduces immunogenicity in vivo Gene Ther 5 740 746
20. OC Farokhzad J Cheng BA Teply I Sherifi S Jon PW Kantoff JP Richie R Langer 2006 Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo Proc Natl Acad Sci USA 103 6315 6320
21. S Song J Xue K Fan G Kou Q Zhou H Wang Y Guo 2005 Preparation and characterization of fusion protein truncated Pseudomonas Exotoxin A (PE38KDEL) in Escherichia coli Protein Expr Purif 44 52 57
22. H Wang S Song G Kou B Li D Zhang S Hou W Qian J Dai L Tian J Zhao Y Guo 2007 Treatment of hepatocellular carcinoma in a mouse xenograft model with an immunotoxin which is engineered to eliminate vascular leak syndrome Cancer Immunol Immunother 56 1775 1783
23. M Dowsett RI Nicholson RJ Pietras 2005 Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance Breast Cancer Res Treat 93 Suppl 1 S11 S18
24. M Pegram D Ngo 2006 Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin): a case study Adv Drug Deliv Rev 58 723 734
25. T Kondo D FitzGerald VK Chaudhary S Adhya I Pastan 1988 Activity of immunotoxins constructed with modified Pseudomonas exotoxin A lacking the cell recognition domain J Biol Chem 263 9470 9475
26. FJ Martin WL Hubbell D Papahadjopoulos 1981 Immunospecific targeting of liposomes to cells: a novel and efficient method for covalent attachment of Fab' fragments via disulfide bonds Biochemistry 20 4229 4238
27. D Blanco MJ Alonso 1997 Development and characterization of protein-loaded poly(lactic/glycolic acid) nanospheres Eur J Pharm Biopharm 43 285 294
28. SH Kim JH Jeong KW Chun TG Park 2005 Target-specific cellular uptake of PLGA nanoparticles coated with poly(L-lysine)-poly(ethylene glycol)-folate conjugate Langmuir 21 8852 8857
29. Y Mo LY Lim 2005 Paclitaxel-loaded PLGA nanoparticles: potentiation of anticancer activity by surface conjugation with wheat germ agglutinin J Control Release 108 244 262
30. M Sandor J Harris E Mathiowitz 2002 A novel polyethylene depot device for the study of PLGA and P(FASA) microspheres in vitro and in vivo Biomaterials 23 4413 4423
31. MM Gaspar D Blanco ME Cruz MJ Alonso 1998 Formulation of L-asparaginase-loaded poly(lactide-co-glycolide) nanoparticles: influence of polymer properties on enzyme loading, activity and in vitro release J Control Release 52 53 62
32. R Zeisig AD Teppke D Behrens I Fichtner 2004 Liposomal 4-hydroxy-tamoxifen: effect on cellular uptake and resulting cytotoxicity in drug resistant breast cancer cells in vitro Breast Cancer Res Treat 87 245 254
33. B Li H Wang D Zhang W Qian S Hou S Shi L Zhao G Kou Z Cao J Dai Y Guo 2007 Construction and characterization of a high-affinity humanized SM5-1 monoclonal antibody Biochem Biophys Res Commun 357 951 956
34. G Kou J Gao H Wang H Chen B Li D Zhang S Wang S Hou W Qian J Dai Y Zhong Y Guo 2007 Preparation and characterization of paclitaxel-loaded PLGA nanoparticles coated with cationic SM5-1 single-chain antibody J Biochem Mol Biol 40 731 739
35. J Schumann D Wolf A Pahl K Brune T Papadopoulos N van Rooijen G Tiegs 2000 Importance of Kupffer cells for T-cell-dependent liver injury in mice Am J Pathol 157 1671 1683
36. HW Wang ME Putt MJ Emanuele DB Shin E Glatstein AG Yodh TM Busch 2004 Treatment-induced changes in tumor oxygenation predict photodynamic therapy outcome Cancer Res 64 7553 7561
37. D Johnston SR Reynolds JC Bystryn 2006 Interleukin-2/liposomes potentiate immune responses to a soluble protein cancer vaccine in mice Cancer Immunol Immunother 55 412 419
38. M Wolf M Wirth F Pittner F Gabor 2003 Stabilisation and determination of the biological activity of L-asparaginase in poly(D, L-lactide-co-glycolide) nanospheres Int J Pharm 256 141 152
39. AE Frankel 2004 Reducing the immune response to immunotoxin Clin Cancer Res 10 13 15
40. JW Park K Hong DB Kirpotin G Colbern R Shalaby J Baselga Y Shao UB Nielsen JD Marks D Moore D Papahadjopoulos CC Benz 2002 Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery Clin Cancer Res 8 1172 1181
41. JW Park DB Kirpotin K Hong R Shalaby Y Shao UB Nielsen JD Marks D Papahadjopoulos CC Benz 2001 Tumor targeting using anti-her2 immunoliposomes J Control Release 74 95 113
42. JW Park CC Benz FJ Martin 2004 Future directions of liposome- and immunoliposome-based cancer therapeutics Semin Oncol 31 196 205
43. C Mamot DC Drummond CO Noble V Kallab Z Guo K Hong DB Kirpotin JW Park 2005 Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo Cancer Res 65 11631 11638
44. PD Scholes AGA Coombes L Illum SS Davis M Vert MC Davies 1993 The preparation of sub-200 nm poly(lactide-co-glycolide) microspheres for site-specific drug delivery J Control Release 25 145 153
45. P Sapra TM Allen 2003 Ligand-targeted liposomal anticancer drugs Prog Lipid Res 42 439 462